17α-Alkan (or alkyn) amide derivatives of estradiol as inhibitors of steroid-sulfatase activity

Steroids

Volumn 64, Issue 12, 1999, Pages 825-833

  Boivin, Roch P ^a   Labrie, Fernand ^a   Poirier, Donald ^a  

^a UNIVERSITÉ LAVAL   (Canada)

Author keywords

Alkylamide; Cancer; Enzyme; Estradiol; Inhibitor; Steroid; Steroid sulfatase

Indexed keywords

4 [4 METHYL 2 [4 [2 (1 PIPERIDINYL)ETHOXY]PHENYL] 7 PIVALOYLOXY 2H 1 BENZOPYRAN 3 YLPHENYL] PIVALATE; ESTRADIOL DERIVATIVE; ESTRONE; ESTRONE SULFATE; FULVESTRANT; N BUTYL 11 (16ALPHA CHLORO 3,17BETA DIHYDROXYESTRA 1,3,5(10) TRIEN 7ALPHA YL) N METHYLUNDECANAMIDE; N BUTYL 11 (3,17BETA DIHYDROXYESTRA 1,3,5(10) TRIEN 7ALPHA YL) N METHYLUNDECANAMIDE; N OCTYL, N METHYL 3 (3',17' BETA DIHYDROXY 1',3',5'(10') ESTRATRIEN 17' ALPHA YL)PROPANAMIDE; RU 51625; STERYL SULFATASE; STERYL SULFATASE INHIBITOR; UNCLASSIFIED DRUG; AMIDE; ARYLSULFATASE; DRUG DERIVATIVE; ENZYME INHIBITOR; ESTRADIOL; ESTROGEN RECEPTOR;

ARTICLE; CONTROLLED STUDY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; ENZYME INHIBITOR INTERACTION; ESTROGEN ACTIVITY; HUMAN; HUMAN CELL; STEROIDOGENESIS; STRUCTURE ACTIVITY RELATION; BREAST TUMOR; CELL CULTURE; CELL DIVISION; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; METABOLISM; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOLOGY; PROTEIN BINDING;

AMIDES; ARYLSULFATASES; BREAST NEOPLASMS; CELL DIVISION; ENZYME INHIBITORS; ESTRADIOL; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MOLECULAR STRUCTURE; PROTEIN BINDING; RECEPTORS, ESTROGEN; STERYL-SULFATASE; TUMOR CELLS, CULTURED;

EID: 0032589988     PISSN: 0039128X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0039-128X(99)00060-4     Document Type: Article

References (39)

1. Von Angerer E. The estrogen receptor as a target for rational drug design. Molecular Biology Intelligence Unit. 1995;1-237 R.G. Landes Company, Austin, TX.
2. Howell A. Anti-estrogens future prospects . Oncology (Huntingt). 11:(suppl. 1):1997;59-64.
3. Magarian R.A., Overacre L.B., Singh S., Meyer K.L. The medicinal chemistry of nonsteroidal anti-estrogens a review . Curr Med Chem. 1:1994;61-204.
4. Macgregor J.I., Jordan V.C. Basic guide to the mechanisms of anti-estrogen action. Pharmacol Rev. 50:1998;151-196.
5. Jordan V.C. Tamoxifen treatment for breast cancer concept to gold standard . Oncology (Huntingt). 11:(suppl. 1):1997;7-13.
6. Labrie C., Martel C., Dufour J.M., Lévesque C., Mérand Y., Labrie F. Novel compounds inhibit estrogen formation and action. Cancer Res. 52:1992;610-615.
7. Gottardis M.M., Robinson S.P., Satyaswaroop P.G., Jordan V.C. Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Res. 48:1988;812-815.
8. Poulin R., Mérand Y., Poirier D., Lévesque C., Dufour J.M., Labrie F. Anti-estrogenic properties of keoxifene, trans-4-hydroxytamoxifen, and ICI 164384, a new steroidal anti-estrogen, in ZR-75-1 human breast cancer cells. Breast Cancer Res Treat. 14:1989;65-76.
9. Chalbos D., Philips A., Galtier F., Rochefort H. Synthetic anti-estrogens modulate induction of pS2 and cathepsin-D messenger ribonucleic acid by growth factors and adenosine 3′,5′-monophosphate in MCF7 cells. Endocrinology. 133:1993;571-576.
10. Gallo MA, Kaufman D. Antagonistic and agonistic effects of tamoxifen: significance in human cancer. Semin Oncol 1997;24(suppl. 1):S1-71-80.
11. Gauthier S., Caron B., Cloutier J., Dory Y.L., Favre A., Larouche D., Mailhot J., Ouellet C., Schwerdtfeger A., Leblanc G., Martel C., Simard J., Mérand Y., Bélanger A., Labrie C., Labrie F. (S)-(+)-4-[7-(2,2-Dimethyl-1-oxopropoxy)-4-methyl-2-[4-[2-(1-piperidinyl)- ethoxy]phenyl]-2H-1-benzopyran-3-yl]-phenyl 2,2-dimethylpropanoate (EM-800) a highly potent, specific, and orally active nonsteroidal anti-estrogen . J Med Chem. 40:1997;2117-2122.
12. Simard J., Sanchez R., Poirier D., Gauthier S., Singh S.M., Mérand Y., Bélanger A., Labrie C., Labrie F. Blockade of the stimulatory effect of estrogens, OH-tamoxifen, OH-toremifene, droloxifene, and raloxifene on alkaline phosphatase activity by the anti-estrogen EM-800 in human endometrial adenocarcinoma Ishikawa cells. Cancer Res. 57:1997;3494-3497.
13. Wakeling A.E., Bowler J. Steroidal pure anti-estrogens. J Endocrinol. 11:1987;R7-R10.
14. Bowler J., Lilley T.J., Pittam J.D., Wakeling A.E. Novel steroidal pure anti-estrogens. Steroids. 54:1989;71-79.
15. Levesque C., Mérand Y., Dufour J.M., Labrie C., Labrie F. Synthesis and biological activity of new halo-steroidal anti-estrogens. J Med Chem. 34:1991;1624-1630.
16. Claussner A., Nédelec L., Nique F., Philibert D., Teusch G., Van de Velde P. 11β-Amidoalkylestradiols, a new series of pure anti-estrogens. J Steroid Biochem Mol Biol. 41:1992;609-614.
17. Wakeling A.E., Dukes M., Bowler J. A potent specific pure anti-estrogen with clinical potential. Cancer Res. 51:1991;3867-3873.
18. Brueggemeier R.W. Aromatase inhibitors - mechanisms of steroidal inhibitors. Breast Cancer Res Treat. 30:1994;31-42.
19. Lombardi P. The irreversible inhibition of aromatase (oestrogen synthetase) by steroid compounds. Curr Pharmaceut Des. 1:1995;23-50.
20. Brodie A.M.H., Njar V.C.O. Aromatase inhibitors in advanced breast cancer mechanism of action and clinical implications . J Steroid Biochem Mol Biol. 66:1998;1-10.
21. Penning T.M. 17β-Hydroxysteroid dehydrogenase inhibitors and inhibitor design . Endocr Rel Cancer. 3:1996;41-56.
22. Tremblay M.R., Poirier D. Overview of a rational approach to design type I 17β-hydroxysteroid dehydrogenase inhibitors without estrogenic activity chemical synthesis and biological evaluation . J Steroid Biochem Mol Biol. 66:1998;179-191.
23. Poirier D., Dionne P., Auger S. A 6β-(thiaheptanamide) derivative of estradiol as inhibitor of 17β-hydroxysteroid dehydrogenase type 1. J Steroid Biochem Mol Biol. 64:1998;83-90.
24. Sam K.M., Auger S., Luu-The V., Poirier D. Steroidal spiro-γ-lactones that inhibit 17β-hydroxysteroid dehydrogenase activity in human placental microsomes. J Med Chem. 38:1995;4518-4528.
25. Poirier D., Ciobanu L.C., Maltais R. Steroid sulfatase inhibitors. Exp Opin Ther Patents. 9:1999;1083-1099.
26. Woo L.W.L., Howarth N.M., Purohit A., Hejaz H.A.M., Reed M.J., Potter B.V.L. Steroidal and nonsteroidal sulfamates as potent inhibitors of steroid sulfatase. J Med Chem. 41:1998;1068-1083.
27. Purohit A., Vernon K.A., Wagenaar Hummelinck A.E., Woo L.W.L., Hejaz H.A.M., Potter B.V.L., Reed M.J. The development of A-ring modified analogues of oestrone-3-O-sulphamate as potent steroid sulphatase inhibitors with reduced oestrogenicity. J Steroid Biochem Mol Biol. 64:1998;269-275.
28. Li P.K., Chu G.H., Guo J.P., Peters A., Selcer K.W. Development of potent non-estrogenic sulfatase inhibitors. Steroids. 63:1998;425-432.
29. Selcer K.W., Hedge P.V., Li P.K. Inhibition of estrone sulfatase and proliferation of human breast cancer cells by nonsteroidal (p-O-sulfamoyl)-N-alkanoyl tyramines. Cancer Res. 57:1997;702-707.
30. Poirier D., Boivin R.P. 17α-Alkyl- or 17α-substituted benzyl-17β-estradiols a new family of estrone-sulfatase inhibitors . Bioorg Med Chem Lett. 8:1998;1891-1896.
31. Poirier D, Labrie F, Boivin RP. 17α-Alkylamide derivatives of estradiol as inhibitors of estrone-sulfatase activity. Xth International Congress on Hormonal Steroids (Quebec City, June 17-21). Program and Abstracts No. 204, 1998. p. 215.
32. 13C nuclear magnetic resonance study of 17α-substituted estradiols. Steroids. 60:1995;830-836.
33. 13C NMR data . Steroids. 62:1997;674-681.
34. Bucourt R., Vignau M., Torelli V., Richard-Foy H., Geynet C., Secco-Millet C., Redeuilh G., Baulieu E.E. New biospecific adsorbents for the purification of estradiol receptor. J Biol Chem. 253:1978;8221-8228.
35. Poirier D., Labrie C., Mérand Y., Labrie F. Synthesis and biological activity of 17α-alkynylamide derivatives of estradiol. J Steroid Biochem Mol Biol. 38:1991;759-774.
36. Sam K.M., Boivin R.P., Tremblay M.R., Auger S., Poirier D. C16 and C17 derivatives of estradiol as inhibitors of 17β-hydroxysteroid dehydrogenase type 1 chemical synthesis and structure-activity relationships . Drug Des Discov. 15:1998;157-180.
37. Luo S., Martel C., Gauthier S., Mérand Y., Bélanger A., Labrie C., Labrie F. Long-term inhibitory effects of a novel anti-estrogen on the growth of ZR-75-1 and MCF-7 human breast cancer tumors in nude mice. Int J Cancer. 73:1997;735-739.
38. Poirier D., Auger S., Mérand Y., Simard J., Labrie F. Synthesis and anti-estrogenic activity of diaryl thioether derivatives. J Med Chem. 37:1994;1115-1125.
39. Poirier D., Mérand Y., Labrie C., Labrie F. D-ring alkylamide derivatives of estradiol effect on ER-binding affinity and anti-estrogenic activity . Bioorg Med Chem Lett. 6:1996;2537-2542.